Topics

Companies Related to "A T Cell-based HIV Vaccine" [Most Relevant Company Matches] RSS

22:05 EST 19th January 2020 | BioPortfolio

Here are the most relevant search results for "A T Cell-based HIV Vaccine" found in our extensive corporate database of over 50,000 company records.

Showing "Cell based Vaccine" Companies 1–25 of 6,700+

Relevant

Genetic Immunity, LLC

Genetic Immunity is a biopharmaceutical company focused on therapeutic vaccine development and commercialization. The lead product, DermaVir vaccine patch, is under clinical evaluation in Hungary and in the USA for the treatment for HIV/AIDS, where resistance, toxicity, adherence and cost limit the use of drugs. The Company’s vaccine composition mimics the successful induction of antiviral immun...


Seqirus

In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.1,2 CVVs are prepared by the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) and associated laboratories, and ...

MabVax Therapeutics, Inc.

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. The company was formed to exploit key aspects of the work of Dr. Philip Livingston and colleagues at MSKCC who have developed cancer vaccines against gangliosides and other carbohydrate antigens that...


ImmunoCellular Therapeutics, Ltd. and BioWa, Inc.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMU...

Cell Essentials, Inc.

Cell Essentials provides contract cell biology-based services facilitating the creation of reagents for use in diagnostics and drug discovery as well as basic research. Major services include the development of custom hybridomas and production of monoclonal antibodies, large scale cell culture, stable cell line development, cell-based assay development, cell banking, and peptide synthesis. Adenovi...

TapImmune, Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T...

SBL VACCIN AB

SBL Vaccines (SBL) is a Swedish registered company with in-house research, development and manufacturing capabilities, marketing our specialist vaccines internationally. A complete vaccine portfolio sourced from global vaccine companies is marketed in the Nordic region by our distribution division based in Stockholm.Our core product Dukoral is an oral vaccine that protects against cholera and trav...

PaxVax, Inc.

PaxVax is a privately held company committed to developing better vaccines to better the world. Established in 2007, PaxVax has a clinical-stage product portfolio, including a cholera vaccine entering Phase 3 and a pandemic H5N1 influenza vaccine entering Phase 2. The company also has vaccines in development for HIV and anthrax under R&D contracts with NIH...

Vaxxas

Vaxxas is a privately-held biotechnology company focused on enhancing the performance of existing and next generation vaccines with its proprietary Nanopatch™ technology platform. Vaxxas’ Nanopatch contains an ultra-high density array of projections – invisible to the naked human eye – that are dry-coated with vaccine. Application of the ...

Sabin Vaccine Institute

Sabin Vaccine Institute is a 501(c)(3) non-profit organization dedicated to reducing human suffering from infectious and neglected diseases. Through its efforts in vaccine research, development and advocacy, Sabin works to provide greater access to vaccines and essential medicines for millions mired in pain, poverty and despair. Founded in 1993 in honor of Dr. Albert B. Sabin, discoverer of the or...

Probiogen AG

ProBioGen is a specialist in mammalian cell engineering and cell culture. We offer our customers a complete service spectrum: from gene to market supply, providing every step from protein expression to cGMP manufacturing, including full project management support. These services are fully integrated to ensure that each individual development step, starting from the vector construction, will contri...

Inviragen, Inc. and PharmaJet, Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclin...

Hawaii Biotech, Inc.

Hawaii Biotech, Inc. is a privately held biopharmaceutical company focused on vaccine research and development. The company is targeting first world vaccines with potentially large markets and attractive margins: a West Nile vaccine targeting the U.S. and Canada; and a dengue fever vaccine for travelers from first world countries to dengue endemic areas. The Company’s vaccine technology was feat...

Pharmexa

Pharmexa is a leading biotech company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. The company has been listed on the Copenhagen Stock Exchange since 2000. The Pharmexa group consists of GemVax AS, a Norwegian subsidiary, developing peptide vaccines for cancer and Pharmexa-Epimmune, a US subsidiary, focusing on T cell epito...

Sinovac Biotech Ltd.

Sinovac Biotech Ltd. is a China-based biopharmaceutical Company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H...

Pure Protein, L.L.C.

Pure Protein is an HLA Center of Excellence - developing immunology tools for therapeutic and diagnostic applications in solid organ and stem cell transplantation, cross-reactive antibody screening, and major autoimmune diseases. Pure Protein was formed in 1999 to commercialize research developed at the University of Oklahoma Health Sciences Center. Pure T...

Pevion Biotech AG

Pevion Biotech AG is a fully independent Swiss vaccine company that develops innovative vaccines for unmet medical needs based on its clinically and commercially validated virosome technology. Its proprietary clinical pipeline includes a first-in-class candidiasis vaccine. A clinical stage malaria vaccine candidate has been successfully out-licensed, and the Company’s technology has been o...

PaxVax Corporation

PaxVax is a privately held company established in 2007 to develop and commercialize innovative and socially responsible vaccines against infectious diseases. PaxVax has a clinical-stage product portfolio, including a cholera vaccine entering Phase 3 and a pandemic H5N1 influenza vaccine entering Phase 2. The company also has vaccines in development for HIV...

LumaCyte

LumaCyte produces label-free, single cell analysis and sorting instrumentation where the use of antibody or genetic labelling is not required for cellular analysis. This revolutionary technology utilizes Laser Force Cytology™ (LFC™) to measure optical and fluidic forces within a microfluidic channel to identify and measure the intrinsic cellular properties of each cell. The multivariate...

ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...

TruMed Systems, Inc.

TruMed Systems, a medical technology company, develops the innovative AccuVax® Vaccine Management System for healthcare professionals. AccuVax is a purpose-built vaccine management solution that safeguards vaccine viability, frees staff time, protects vaccine investment, and maximizes patient safety so that providers can focus on care delivery. AccuVax is ...

ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...

World of Health Biotech Co.Ltd

Anti HBV Specific Active Immunotherapy (Anti HBV Therapeutic Vaccine) using recombinant hepatitis B vaccine (standard HBV vaccine) as an immunogenic specific antigen and several cytokines as an immune adjuvant is a new antiviral approach for chronic HBV infection. The first and most critical setp in the design of an anti HBV therapeutic vaccine is the selection of the specific antigens that will b...

Biotech Synergy

Biotech Synergy has secured in San Diego the necessary competences to bring this promising multi epitope cancer vaccine to latest stage development. Contrary to Dendreon individualized vaccine, EP-2101 is made of 10 peptides and is an off the shelf readily available vaccine for the HLA-A2 population, which represents 45% of the global NSCLC patients (100,0...

PaxVax Inc

PaxVax is a privately held company established in 2007 to develop and commercialize innovative vaccines against infectious diseases. PaxVax has a clinical-stage product portfolio, including a cholera vaccine that recently initiated Phase 3 clinical trials and a pandemic H5N1 influenza vaccine entering Phase 2 clinical trials. The company also has vaccines ...


More From BioPortfolio on "A T Cell-based HIV Vaccine"

Quick Search

Corporate Database Quicklinks